Nicole McNeil is an associate in the London office of Latham & Watkins, having previously spent several years in the firm’s Boston office.

Ms. McNeil advises public company clients on general securities, corporate governance, and public reporting matters, including compliance with Exchange Act disclosure requirements, proxy rules, insider reporting and trading restrictions, stock exchange governance rules, and the Sarbanes-Oxley Act of 2002 and related regulations.

Her clients include both US and foreign New York Stock Exchange and Nasdaq-listed companies across a broad range of industries, with a particular focus on life sciences, technology, and retail.

Prior to law school, Ms. McNeil worked as a paralegal in the dedicated Health Care Fraud Unit of the United States Attorney's Office.

Ms. McNeil received a BA in Biology from Williams College and a JD from Cornell Law School.

Ms. McNeil's experience includes representing:

  • Issuers and underwriters in connection with capital markets transactions predominately in the life sciences and healthcare industries, including initial public offerings and equity follow-on offerings
  • Ongoing public company clients with respect to general corporate governance matters, SEC compliance and securities law issues, disclosure and reporting obligations, including preparation of SEC disclosure documents, and listed company obligations
  • Start-up companies in venture financing transactions, as well as matters related to general corporate governance, securities law issues, employment, and intellectual property

Ms. McNeil's representative transactions as company counsel include advising:

  • Evelo Biosciences in its US$85 million initial public offering of its common stock 
  • Homology Medicines in its US$165 million initial public offering of its common stock and follow-on offerings
  • Press Ganey in its US$255 million initial public offering of its common stock
  • Selecta Biosciences in its US$70 million initial public offering of its common stock and follow-on offerings
  • BIND Therapeutics in its US$70 million initial public offering of its common stock and follow-on offerings

Ms. McNeil's representative transactions as underwriters' counsel include advising:

  • Jefferies, Leerink Partners, and BMO Capital Markets in scPharmaceuticals’ US$102 million initial public offering
  • Bank of America in Aileron Therapeutics’ US$56 million initial public offering
  • Goldman Sachs and Morgan Stanley in US$144 million and US$230 million follow-on offerings by Blueprint Medicines
  • UBS and Morgan Stanley in follow-on offerings by Akebia Therapeutics
  • BMO and Stifel in follow-on offerings by Tetraphase Pharmaceuticals

Bar Qualification

  • Massachusetts


  • JD, Cornell Law School, 2014
  • BA, Williams College, 2009

Languages Spoken

  • English